Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL7157449 | 0.93 | SLC6A4 (0.39) | SLC6A4SLC6A3SLC6A2OPRM1 | |
| SCHEMBL7568500 | 0.86 | CYP2D6 (0.48) | SLC6A4SLC6A3SLC6A2OPRM1 | |
| SCHEMBL5730907 | 0.86 | OPRM1 (0.40) | OPRM1 | |
| SCHEMBL3656139 | 0.86 | ALDH1A1 (0.47) | SLC6A4SLC6A3SLC6A2OPRM1 | |
| SCHEMBL7464514 | 0.86 | SLC6A2 (0.48) | SLC6A4SLC6A3SLC6A2OPRM1 | |
| SCHEMBL1012743 | 0.86 | SLC6A2 (0.48) | SLC6A4SLC6A3SLC6A2OPRM1 | |
| SCHEMBL7156275 | 0.84 | OPRM1 (0.47) | SLC6A4SLC6A3SLC6A2OPRM1 | |
| SCHEMBL8347022 | 0.84 | HRH3 (0.37) | SLC6A4SLC6A3SLC6A2OPRM1 | |
| SCHEMBL7160342 | 0.83 | ALDH1A1 (0.35) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15956392 | 0.80 | OPRM1 (0.46) | SLC6A4SLC6A3SLC6A2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585976-B2 | Automated radiolabelling method | GE HEALTHCARE LIMITED (GB) | 2017-03-07 | — | — | US | claimed |
| WO-2023219199-A1 | MANUFACTURING METHOD FOR FP-CIT PRECURSOR, AND MANUFACTURING METHOD FOR [18F]FP-CIT USING FP-CIT PRECURSOR MANUFACTURED THEREBY | (주)듀켐바이오 | 2023-11-16 | — | — | WO | disclosed |
| EP-1118674-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | NIHON MEDIPHYSICS CO LTD (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-2212320-A1 | CHEMICAL SYNTHESIS OF I-124BETA CIT IODINE-124 [2-BETA-CARBOMETHOXY-3BETA- (4. -IODOPHENYL) -TROPANE] FOR PET INVESTIGATIONS AND FOR RADIOTHERAPY | A.C.O.M. Advanced Center Oncology Macerata S.p.a. (IT) | 2010-08-04 | — | — | EP | disclosed |
| EP-2212320-A1 | CHEMICAL SYNTHESIS OF I-124BETA CIT IODINE-124 [2-BETA-CARBOMETHOXY-3BETA- (4. -IODOPHENYL) -TROPANE] FOR PET INVESTIGATIONS AND FOR RADIOTHERAPY | A.C.O.M. Advanced Center Oncology Macerata S.p.a. (IT) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009143985-A1 | NEW MOLECULE 5-HYDROXY-L-(4-HYDROXY-3-[124I]IODO-5-METHOXYPHENYL)-7- (4-HYDROXY-3-METHOXYPHENYL)-L,4,6-HEPTATRIEN-3-ONE FOR PET INVESTIGATIONS AND RADIOTHERAPY. | SPARKLE S.R.L. (IT) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009141137-A2 | NEW MOLECULE [124I][2-(3'-IODO-4'-METHYLAMINOPHENYL)-6-HYDROXY-BENZOTHIALZOLE] FOR PET INVESTIGATIONS AND RADIOTHERAPY | SPARKLE S.R.L. (IT) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009046897-A1 | CHEMICAL SYNTHESIS OF I-124BETA CIT IODINE-124 [2-BETA-CARBOMETHOXY-3BETA- (4. -IODOPHENYL) -TROPANE] FOR PET INVESTIGATIONS AND FOR RADIOTHERAPY | A.C.O.M ADVANCED CENTER ONCOLOGY MACERATA S.P.A. (IT) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009046897-A1 | CHEMICAL SYNTHESIS OF I-124BETA CIT IODINE-124 [2-BETA-CARBOMETHOXY-3BETA- (4. -IODOPHENYL) -TROPANE] FOR PET INVESTIGATIONS AND FOR RADIOTHERAPY | A.C.O.M ADVANCED CENTER ONCOLOGY MACERATA S.P.A. (IT) | 2009-04-16 | — | — | WO | disclosed |
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-04-03 | — | — | US | disclosed |
| EP-1118674-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | Nihon Medi-Physics Co., Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| US-5750089-A | Halogenated neuroprobe for mapping monoamine reuptake sites | NEURO IMAGING TECHNOLOGIES, LLC (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0831941-A1 | IODINATED NEUROPROBES FOR MAPPING MONOAMINE REUPTAKE SITES | Research Biochemicals, Limited Paternership, doing business as Research biochemicals International (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5698179-A | Iodinated neuroprobe for mapping monoamine reuptake sites | NEURO IMAGING TECHNOLOGIES, LLC (US) | 1997-12-16 | — | — | US | disclosed |
| WO-1996039198-A1 | IODINATED NEUROPROBES FOR MAPPING MONOAMINE REUPTAKE SITES | RESEARCH BIOCHEMICALS, LIMITED PARTNERSHIP, doing business as RESEARCH BIOCHEMICALS INTERNATIONAL, A MASSACHUSETTS LIMITED PARTNERSHIP, WHOSE SOLE GENERAL PARTNER IS RBI MANAGEMENT, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0703791-A4 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RES BIOMED LP (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0703791-A1 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RESEARCH BIOMEDICALS LIMITED PARTNERSHIP (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5439666-A | Central nervous system | RESEARCH BIOCHEMICALS LIMITED PARTNERSHIP (US) | 1995-08-08 | — | — | US | disclosed |
| WO-1995001184-A1 | AN IODINATED NEUROPROBE FOR MAPPING MONOAMINE REUPTAKE SITES | RESEARCH BIOCHEMICALS LIMITED PARTNERSHIP (US) | 1995-01-12 | — | — | WO | disclosed |
| US-5310912-A | Ester-substituted nortropane | RESEARCH BIOCHEMICALS LIMITED PARTNERSHIP (US) | 1994-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | CES2, FTO, HAAO | SLC6A4 1204/4885SLC6A3 712/4885SLC6A2 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.